Q2 2026 WAVE Life Sciences Ltd Earnings Call Transcript

Jul 30, 2026 / 12:30 PM GMT

Release Date Price: €4.94 (-2.18%)

Transcript 8-K

Key Points

Positve

WVE-007 demonstrated robust and durable silencing of INHBE in Phase 1, supporting potential for once or twice yearly dosing in obesity.
WVE-007 showed substantial reductions in visceral fat and subcutaneous fat without muscle loss, a key differentiator from incretin therapies.
WVE-006 for AATD achieved a compelling therapeutic profile, including ZAAT reduction and dynamic AAT response, positioning it for a potential accelerated approval pathway.
WAVE is advancing a second RNA editing candidate, WVE-008, for PNPLA3 liver disease, targeting a high unmet need with strong human genetic support.
The company has a strong cash position of $490.6 million, expected to fund operations into Q3 2028, supporting pipeline advancement.

Negative

Net loss increased significantly to $69.4 million in Q2 2026 from $15.5 million in Q2 2025, driven by higher R&D and G&A expenses.
Revenue declined to $2.3 million in Q2 2026 from $8.7 million in the prior year quarter, reflecting lower collaboration income.
WVE-007's Phase 2a trial is still early, and the magnitude of weight loss and fat reduction in higher BMI patients remains to be confirmed.
The regulatory pathway for WVE-006 is still under discussion, with an FDA meeting planned for late summer, creating uncertainty on timelines.
The company is seeking partnerships for its HD and DMD programs, indicating a strategic shift and potential challenges in advancing these assets independently.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

WVE.OQ - WAVE Life Sciences Ltd
Q2 2026 WAVE Life Sciences Ltd Earnings Call
Jul 30, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to Wave Life Sciences second quarter 2026 earnings call. We ask that you please hold all questions until the completion of the formal remarks. At rich time, you'll be given instructions for the question-and-answer session.

Also, as a reminder, this conference is being recorded today.

I will now turn the call over to Kate Roush, Vice President of Corporate Affairs and Investor Relations.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good morning to everyone on the call. Earlier this morning, we issued a press

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.